Policymaking for orphan drugs and its challenges

AMA Journal of Ethics

Volumn 17, Issue 8, 2015, Pages 776-779

  Rhee, Taeho Greg ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; DRUG MANUFACTURE; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; HUMAN; LEGISLATION AND JURISPRUDENCE; MANAGEMENT; RARE DISEASES; UNITED STATES;

DRUG INDUSTRY; FINANCING, GOVERNMENT; HUMANS; ORPHAN DRUG PRODUCTION; POLICY MAKING; RARE DISEASES; UNITED STATES;

EID: 84965186995     PISSN: None     EISSN: 23766980     Source Type: Journal    
DOI: 10.1001/journalofethics.2015.17.8.pfor2-1508     Document Type: Review

References (23)

1. US Food and Drug Administration. Developing products for rare diseases and conditions. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm. Updated June 8, 2015. Accessed June 15, 2015.
2. Field ML, Boat TF, eds. Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: National Academies Press; 2010.
3. Franco P. Orphan drugs: the regulatory environment. Drug Discov Today. 2013;18(3-4):165.
4. Orphan Drug Act, Pub L No. 97-414, 96 Stat 2049-2057.
5. Field, Boat, 25.
6. Simoens S, Cassiman D, Dooms M, Picavet E. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs. 2012;72(11):1437-1443.
7. US Food and Drug Administration. Orphan Drug Act: relevant excerpts (Public Law 97-414, as amended): last updated August 2013. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm364750.htm. Updated June 8, 2015. Accessed June 15, 2015.
8. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy. 2010;95(2-3):226.
9. Field, Boat, 36.
10. Lichtenberg FR. The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007. Eur J Health Econ. 2013;14(1):41-56.
11. Lichtenberg FR. The effect of new drugs on mortality from rare diseases and HIV. Cambridge, MA: National Bureau of Economic Research; 2001. NBER Working Paper 8677. http://www.nber.org/papers/w8677.pdf. Accessed June 17, 2015.
12. Lichtenberg, The impact of new (orphan) drug approvals, 41.
13. Cȏté A, Keating B. What is wrong with orphan drug policies? Value Health. 2012;15(8):1185-1191.
14. Haffner ME, Torrent-Farnell J, Maher PD. Does orphan drug legislation really answer the needs of patients? Lancet. 2008;371(9629):2041-2044.
15. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
16. Wellman-Labadie, Zhou, 226.
17. Hemphill TA. Extraordinary pricing of orphan drugs: is it a socially responsible strategy for the US pharmaceutical industry? J Bus Ethics. 2010;94:229.
18. Casali PG; Executive Committee of ESMO. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2007;18(12):1923-1925.
19. Gavel SJ. The oncology pipeline: maturing, competitive, and growing? Oncol Bus Rev. September 2008:14-16.
20. Seachrist L. Senators seek reform of Orphan Drug Act. J Natl Cancer Inst. 1993;85(24):1984-1985.
21. Haffner, Torrent-Farnell J, Maher, 2042.
22. Wellman-Labadie, Zhou, 225.
23. Cȏté, Keating, 1185.